Clinical trials: Carcinoma, Non-Small-Cell Lung Cancer
Carcinoma, Non-Squamous Non-Small Cell Lung
A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
This randomized Phase III, multicenter, open-label study designed to evaluate the safety and efficacy of atezolizumab (an engineered anti-programmed death-ligand 1 [PD-L1] antibody) in combination with carboplatin+nab-paclitaxel…
- Trial name
- IMpower130 (NCT02367781)
- Testing
- Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Carboplatin, Nab-Paclitaxel
- Where
- 132 sites in United States, Belgium and 6 more
- Volunteers
- 723 people
- Sponsor
- Hoffmann-La Roche
Extensive Stage Small Cell Lung Cancer, Healthy, no Evidence of Disease
Impacts of Exercise on Prognostic Biomarkers in Lung Cancer Patients
This randomized pilot clinical trial studies exercise intervention in improving quality of life and exercise capacity and reducing inflammation and oxidative stress in patients with lung cancer and their support persons.
- Conditions
- Extensive Stage Small Cell Lung Cancer, Healthy, no Evidence of Disease, Limited Stage Small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer
- Trial name
- NCT01999881
- Testing
- exercise intervention, standard follow-up care, quality-of-life assessment
- Where
- 2 sites in United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Esophageal Cancer, Lung Cancer
PET Scan in Patients With Lung and Esophageal Cancers That May Be Removed by Surgery
RATIONALE: Imaging procedures, such as fludeoxyglucose F 18 positron emission tomography (PET) scans, may improve the ability to detect lung and esophageal cancer or their recurrence.
- Trial name
- NCT00002930
- Testing
- positron emission tomography, fludeoxyglucose F 18
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Urinary Bladder Cancer, Bladder Tumors
A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer
The purpose of this study is to evaluate if the treatment with NEO-PV-01 + adjuvant in combination with nivolumab is safe and useful for patients with certain types of cancer.
- Conditions
- Urinary Bladder Cancer, Bladder Tumors, Transitional Cell Carcinoma of the Bladder, Malignant Melanoma
- Trial name
- NCT02897765
- Testing
- NEO-PV-01, Nivolumab, Adjuvant
- Where
- 9 sites in United States
- Volunteers
- 34 people
- Sponsor
- BioNTech US Inc.
Metastatic Non Small Cell Lung Cancer
Efficacy & Safety Study of Lorlatinib in ALK/ROS1 Metastatic NSCLC Patients With Compassionate Use Treatment
This is an observational, non-interventional, retrospective, multicentre and nationwide study. The information will be obtained retrospectively, in most cases when the treatment has already ended.
- Trial name
- LORLAPULM (NCT05167500)
- Testing
- Lorlatinib
- Where
- 25 sites in Spain
- Volunteers
- 118 people
- Sponsor
- Fundación GECP
Non Small Cell Lung Cancer
Ponatinib in Advanced NSCLC w/ RET Translocations
This research study is a Phase II clinical trial, which tests the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific cancer.
- Trial name
- NCT01813734
- Testing
- Ponatinib
- Where
- 5 sites in United States
- Volunteers
- 9 people
- Sponsor
- Massachusetts General Hospital
Non-Small-Cell Lung Carcinoma, Colorectal Cancer
A Study to Compare Tissue and Liquid Biopsies in People With Different Types of Cancer
In study, liquid biopsy samples will be obtained from non-small cell lung cancer (NSCLC) including Squamous cell carcinoma, Adenocarcinoma and large cell carcinoma, colorectal carcinoma (CRC) and pancreatic ductal adenocarcinoma…
- Conditions
- Non-Small-Cell Lung Carcinoma, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT05708599
- Testing
- Liquid biopsy
- Where
- Germany
- Volunteers
- 102 people
- Sponsor
- Boehringer Ingelheim
Non-Small Cell Lung Cancer, c-MET
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Non-small cell lung cancer (NSCLC) is a common type of lung cancer where abnormal cells in the lungs grow out of control. The purpose of this study is to assess adverse events and change in disease activity of telisotuzumab…
- Trial name
- NCT07155187
- Testing
- Telisotuzumab Adizutecan, Standard of Care, Osimertinib
- Where
- 117 sites in United States, Australia and 18 more
- Volunteers
- 490 people
- Sponsor
- AbbVie
Lung Cancer, Non-small Cell Lung Cancer Stage I
Volatolomic and Proteomic Profile for Early Diagnosis of Lung Cancer
The goal of this prospective, case-control study is to discover the specific "omics" biomarkers of early stage of lung cancer using the non-invasive samples (breath, urine and serum) in a total of 200 subjects (100 healthy…
- Conditions
- Lung Cancer, Non-small Cell Lung Cancer Stage I, Non-small Cell Lung Cancer Stage II, Lung Cancer Diagnosis
- Trial name
- NCT06341387
- Testing
- Breath, urine and blood analysis
- Where
- Italy
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- European Institute of Oncology
Lung Cancer
S0002 - A Program to Quit Smoking With or Without Bupropion in Treating Patients With Stage I or II Non-Small Cell Lung Cancer Who Have Undergone Surgery
RATIONALE: A program that includes bupropion may be more effective in helping early-stage lung cancer patients to quit smoking. It is not yet known if a program to quit smoking is more effective with or without bupropion.
- Trial name
- NCT00032084
- Testing
- smoking cessation intervention, bupropion hydrochloride, nicotine
- Where
- 176 sites in United States, Puerto Rico
- Volunteers
- 10 people
- Sponsor
- SWOG Cancer Research Network
Melanoma, Non Small Cell Lung Cancer
PDR001 + Panobinostat for Melanoma and NSCLC
The purpose of this research study is to find the dose of the study drug PDR001 that, when given in combination with the drug Panobinostat, results in the best outcomes for metastatic melanoma and non-small cell lung cancer…
- Trial name
- NCT03982134
- Testing
- PDR001, Panobinostat
- Sponsor
- Muhammad Furqan
Non-Small Cell Lung Cancer
A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor (HER)2 Immunohistochemistry (IHC)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
This is a Phase 2, multicenter study designed to evaluate the efficacy and safety of trastuzumab emtansine administered as a single-agent in participants with HER2-positive (HER2 IHC 2+ or HER2 IHC 3+) advanced or metastatic…
- Trial name
- NCT02289833
- Testing
- Trastuzumab Emtansine
- Where
- 23 sites in United States, Germany and 5 more
- Volunteers
- 49 people
- Sponsor
- Hoffmann-La Roche
Solid Tumor, Medullary Thyroid Cancer
A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation
The reason for this study is to see if the study drug selpercatinib is safe and effective in participants in China with rearranged during transfection (RET) fusion-positive solid tumors, medullary thyroid cancer (MTC) and other…
- Trial name
- LIBRETTO-321 (NCT04280081)
- Testing
- Selpercatinib
- Where
- 13 sites in China
- Volunteers
- 77 people
- Sponsor
- Eli Lilly and Company
Lung Neoplasms
Validation of Molecular Diagnostic Thecnologies for Lung Cancer Patients.
This is a non-interventional multi-center with investigational sites in Chile and Brasil diagnostic study to validate novel diagnostic technologies, such as Next Generation Sequencing (NGS) from both tissue and blood compared to…
- Trial name
- NIRVANA (NCT03220230)
- Where
- 37 sites in Brazil, Chile and 1 more
- Volunteers
- 4,240 people
- Sponsor
- Pfizer
Lung Cancer, Perioperative/Postoperative Complications
Lung Rehabilitation in Treating Patients With Chronic Obstructive Pulmonary Disease Who Are Undergoing Surgery for Lung Cancer
RATIONALE: Exercise may help improve lung function and lessen complications of surgery in patients with chronic obstructive pulmonary disease who are undergoing surgery for lung cancer.
- Conditions
- Lung Cancer, Perioperative/Postoperative Complications, Pulmonary Complications, Tobacco Use Disorder
- Trial name
- NCT00363428
- Testing
- exercise intervention, smoking cessation intervention, counseling intervention
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Mayo Clinic
Non-small Cell Lung Cancer, Leptomeningeal Metastasis
Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis
The primary objective of this clinical study is to evaluate the efficacy of high-dose furmonertinib combined with bevacizumab and pemetrexed (triple therapy) in the treatment of non-small cell lung cancer (NSCLC) with…
- Conditions
- Non-small Cell Lung Cancer, Leptomeningeal Metastasis, EGFR Gene Mutation
- Trial name
- NCT06643000
- Testing
- furmonertinib
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Henan Cancer Hospital
OligoProgressive Metastatic Disease, Non-Small Cell Lung Cancer
Standard-of-care Systemic Therapy With or Without Local Therapy in Patients With Oligoprogressive Non-Small Cell Lung Cancer(NSCLC）
This is a randomized, controlled, phase II/III clinical study to evaluate the efficacy and safety of stand-of-care systemic therapy with local therapy versus stand-of-care systemic therapy in patients with oligoprogressive…
- Trial name
- NCT07076693
- Testing
- Radiotherapy or Surgery, Standard Medical Therapy
- Where
- China
- Volunteers
- 97 people
- Sponsor
- Shanghai Chest Hospital
Lung Neoplasms, Carcinoma Non-small-cell Lung
A Clinical Test for the Treatment of Multifocal Lung Cancers Using Genome Sequencing
The investigators are doing this research to see if they can use small tissue samples or fluid to develop a test that will determine if the tissue samples are related or not related to each other.
- Trial name
- NCT02705404
- Testing
- Multifocal Tissue Banking
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Mayo Clinic
Prostate Cancer, Renal Cell Carcinoma
Characterization of Circulating Tumor Cells Captured by c-MET (CTC-MET)
This pilot study will aim to determine whether circulating tumor cells (CTCs) can be captured using the novel cMET based ferrofluid.
- Conditions
- Prostate Cancer, Renal Cell Carcinoma, Bladder Cancer, Colorectal Cancer
- Trial name
- NCT02080650
- Testing
- Mesenchymal-marker based ferrofluid (c-MET), Epithelial cell adhesion molecule (EpCAM) ferrofluid
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Duke University
Non-Small Cell Lung Cancer
Time Trends in Waiting Times of NSCLC Patients.
A large group of non-small cell lung cancer patients is treated with radiotherapy. Delivery of very high radiation doses is needed to obtain local control, but due to the large tumor and nodal volume this is often impossible…
- Trial name
- NCT01946490
- Where
- Netherlands
- Sponsor
- Maastricht Radiation Oncology
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.